Toronto, Ontario / ACCESSWIRE / October 29, 2014 / The Board of Directors of Mindesta, Inc (OTCBB: MDST) is pleased to announce the appointment of Steve Abboud to the Advisory Board of CTT Pharmaceuticals, effective immediately.
"As part of CTT's overall business strategy, we required a subject matter expert within the medicinal marijuana industry. Steve brings a wealth of knowledge in all facets of medicinal marijuana, therefore his perspective on our goals as well as his wealth of International contacts, will be highly valued. "stated Dean Hanisch, President -CTT Pharmaceuticals
Steve has over 12 years of relevant Medicinal Marijuana experience and is an expert grower who currently consults for various MMPR (Marijuana for Medical Purposes Regulations) companies and applicants. A Horticulturist with experience growing a variety of plants, Steve has an excellent understanding of the cannabis plant's composition. As a provider he has worked at the patient level and understands the therapeutic values of the plant. These two attributes have made Steve instrumental in acting as a liaison between caregivers (patient) and growers. In addition to Cannabis, Steve has been involved in the cultivation and extraction within Nutraceuticals, with medicinal plants such as St. John's Wort, Ginseng, Thornberry and White Lupine.
"His knowledge of extraction within Nutraceuticals will be useful in developing our oral film as Steve understands the plants composition and limitations. In order to fulfill our ultimate goal of improving delivery, lowering dependency, and creating better adherence and safety for opioids, we require a variety of specific cross industry skill sets. To this end, as we continue to build our team, Steve's expertise completes another piece of the puzzle." said Dr. Pankaj Modi, CEO- CTT Pharmaceuticals,
ABOUT CTT PHARMACEUTICALS:
CTT Pharma has invented and developed an ideal intra-oral, sublingual, fast-dissolving wafer drug delivery system, complete with a mobile backend tracking software designed to increase patient compliance and prevent physical addiction.
CTT Pharma's principal asset is a patented, orally administered, fast dissolving wafer (the "Wafer")
The Wafer formulation is protected by Canadian Patent Number CA 2624110 C and US Patent Number 8,823,401 B2. The Canadian Patent, is a blanket patent covering most pharmaceutical agents (an open patent) and US Patent consist of approved opiates; such as Fentanyl, Morphine, Codeine etc.
CTT Pharma's primary mission is to lower addiction and improve overall compliance within the pain management market, specifically opiates, through the use of improved drug delivery and novel IT technology. This technology platform will be targeting both the human and pet (Veterinarian) markets.
CTT Pharma's Oral fast dissolving drug delivery systems will consist of films and wafers that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system, mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficiency of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing.
Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its technology will be the first to gain widespread use in major markets such as Pain Management (MedWafe), Veterinary Medicine(VetWafe) as well as Medicinal Marijuana(Cannawafe).
For additional information, please contact:
Dean Hanisch, President - CTT Pharmaceuticals: Tel: 613 612-6060
Website: www.cttpharmaceuticals.com
________________________________________________________________________________________________________
Forward Looking Statements:
This press release contains forward-looking statements, which can be identified by the use of statements that include words such as "could", "potential", "believe", "expect", "anticipate", "intend", "plan", "likely", "will" or other similar words or phrases. These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. The Company does not intend, and does not assume any obligation, to update forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by applicable securities laws. Readers should not place undue reliance on forward-looking statements.
NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THE CONTENTS OF THIS RELEASE
SOURCE: Mindesta, Inc